- Home
- RRC vs ROIV Comparison
RRC vs ROIV Comparison
Compare RRC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RRC | ROIV |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 20.7B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RRC | ROIV |
|---|---|---|
| Price | $44.84 | $27.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | ★ $42.44 | $27.56 |
| AVG Volume (30 Days) | 3.3M | ★ 4.5M |
| Earning Date | 04-21-2026 | 02-06-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | ★ 151.38 | N/A |
| EPS | ★ 2.74 | N/A |
| Revenue | ★ $3,115,515,000.00 | $29,053,000.00 |
| Revenue This Year | $10.34 | N/A |
| Revenue Next Year | $8.73 | $594.84 |
| P/E Ratio | $16.49 | ★ N/A |
| Revenue Growth | ★ 28.90 | N/A |
| 52 Week Low | $30.32 | $8.73 |
| 52 Week High | $46.19 | $30.33 |
Technical Indicators
Market Signals| Indicator | RRC | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 72.05 | 49.52 |
| Support Level | $34.07 | $26.94 |
| Resistance Level | N/A | $27.94 |
| Average True Range (ATR) | 1.38 | 0.96 |
| MACD | 0.19 | -0.38 |
| Stochastic Oscillator | 76.81 | 18.54 |
Price Performance
Historical ComparisonAbout RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.2 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.